阿玛琳 2026年季度报告

☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACTOF 1934For the quarterly period ended March 31, 2026 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACTOF 1934 Amarin Corporation plc(Exact Name of Registrant as Specified in its Charter) Not applicable(I.R.S. EmployerIdentification No.) Dublin2, Co. Dublin,D02 K7K5, Ireland(Zip Code) Registrant’s telephone number, including area code: +353 (0) 1 6699 020 Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file suchreports), and (2) has been subject to such filing requirements for the past 90 days.YES☒NO☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period thatthe registrant was required to submit such files).YES☒NO☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer☐Non-accelerated filer☐Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).YES☐NO☒ 419,382,177 Ordinary Shares, 50 pence par value per share, were outstanding as of April 24, 2026, including 20,533,349 OrdinaryShares held as American Depositary Shares (ADSs), each representing 20 Ordinary Shares. INDEX TO FORM 10-Q PART I – Financial Information Item 1.Financial Statements (unaudited):Condensed Consolidated Balance Sheets as of March 31, 2026 and December 31, 20253Condensed Consolidated Statements of Operations for the three months ended March 31, 2026 and20254Condensed Consolidated Statement of Changes in Stockholders’ Equity for the three months endedMarch 31, 2026 and 20255Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2026 and20256Notes to Condensed Consolidated Financial Statements7Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations27Item 3.Quantitative and Qualitative Disclosures about Market Risk37Item 4.Controls and Procedures37 PART II – Other Information Item 1.Legal Proceedings38Item 1A.Risk Factors38Item 2.Unregistered Sales of Equity Securities and Use of Proceeds38Item 5.Other Information38Item 6.Exhibits39 PART I AMARIN CORPORATION PLCCONDENSED CONSOLIDATED BALANCE SHEETS(Unaudited, in thousands, except share amounts) AMARIN CORPORATION PLCCONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS’ EQUITY(Unaudited, in thousands, except share amounts) AMARIN CORPORATION PLCCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(Unaudited, in thousands) AMARIN CORPORATION PLCNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (1)Nature of Business and Basis of Presentation Nature of Business Amarin Corporation plc, or Amarin, or the Company, is a pharmaceutical company focused on the commercialization anddevelopment of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. The Company is commercialized in theUnited States, or the U.S., under the brand name VASCEPA®(icosapent ethyl). VASCEPA, under the brand name VAZKEPA,hereinafter along with VASCEPA, collectively referred to as VASCEPA is also commercialized in various other countriesthroughout the world. The Company and seven commercial partners are in various stages: seeking or maintaining regulatory approval, obtaininggovernment or private pricing and reimbursement, and/or commercialization. VASCEPA and VAZKEPA approvals andapplications for approval globally reference either the U.S. New Drug Application, or NDA, core dossier or the EuropeanMedicines Agency, or EMA, core dossier. (1) As part of the Recordati partnership, agreements with Vianex S.A "Vianex" (Greece), Magnapharm Marketing &Sales Romania S.R.L. "Magnapharm" (Romania), and Salus, Veletrgovina, d.o.o, "Salus" (Slovenia) will betransitioned to Recordati. VASCEPA was first approved by the U.S. Food and Drug Administration, or U.S. FDA, in July 2012 for use as an adjunct to diet toreduce triglyceride, or TG, levels in adult patients with severe (>500 mg/dL) hypertriglyceridemia, or the MARINE indication